Assessing drug-likeness--what are we missing?

@article{Vistoli2008AssessingDA,
  title={Assessing drug-likeness--what are we missing?},
  author={Giulio Vistoli and Alessandro Pedretti and Bernard Testa},
  journal={Drug discovery today},
  year={2008},
  volume={13 7-8},
  pages={285-94}
}
The concept of drug-likeness helps to optimise pharmacokinetic and pharmaceutical properties, for example, solubility, chemical stability, bioavailability and distribution profile. A number of molecular descriptors have emerged as reasonably informative and predictive, for example, the Rule-of-Five. Here, we review some current approaches, then discuss their major shortcoming, namely the static nature of the structural features and physicochemical properties they encode. As we demonstrate… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Prodrug objectives and design

  • B. Testa, H. van de Waterbeemd, J. B. Taylor, D. J. Triggle, M. Feher, J. M. Schmidt
  • ADME - Tox Approaches
  • 2007

The conformational and property space of acetylcholine bound to muscarinic receptors: an entropy component accounts for the subtype selectivity of acetylcholine

  • G Vistoli
  • Arch. Biochem
  • 2007

A pactical view of ‘‘druggability’

  • Keller, T.H
  • J. Med. Chem
  • 2006

Similar Papers

Loading similar papers…